Proliferative diabetic retinopathy

Retina Fifth Edition

Volumn , Issue , 2012, Pages 969-1000

  Silva, Paolo A S ^a,b,c,d   Cavallerano, Jerry D ^a,d   Sun, Jennifer K ^a,d,e   Blodi, Barbara A ^f   Davis, Matthew D ^g   Aiello, Lloyd M ^g   Aiello, Lloyd Paul ^a,b,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d JOSLIN DIABETES CENTER   (United States)

^e Center for Eye Research and Education   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g University of Wisconsin School of Medicine and Public Health ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906800708     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0737-9.00048-5     Document Type: Chapter

References (193)

1. Diabetic Retinopathy Study Research Group Preliminary report on effects of photocoagulation therapy Am J Ophthalmol 81 1976 383-396.
2. Diabetic Retinopathy Study Research Group Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study Arch Ophthalmol 97 1979 654-655.
3. Klein R., Klein BE., Moss SE., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years Arch Ophthalmol 107 1989 237-243.
4. Klein R., Klein BE., Moss SE., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more Arch Ophthalmol 107 1989 244-249.
5. Klein R., Knudtson MD., Lee KE., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XXII. The twenty-five-year progression of retinopathy in persons with type 1 diabetes Ophthalmology 115 11 2008 1859-1868.
6. Aiello LP., Cahill MT., Wong JS Systemic considerations in the management of diabetic retinopathy Am J Ophthalmol 132 2001 760-766.
7. Klein R., Klein BE., Moss SE Epidemiology of proliferative diabetic retinopathy Diabetes Care 15 1992 1875-1891.
8. Hovind P., Tarnow L., Rossing K., et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes Diabetes Care 26 2003 1258-1264.
9. Klein R., Klein BE., Moss SE., et al. The medical management of hyperglycemia over a 10-year period in people with diabetes Diabetes Care 19 1996 744-750.
10. Wong TY., Mwamburi M., Klein R., et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis Diabetes Care 32 2009 2307-2313.
11. Klein R., Klein BE Are individuals with diabetes seeing better? A long-term epidemiological perspective Diabetes 59 2010 1853-1860.
12. Stefansson E Ocular oxygenation and the treatment of diabetic retinopathy Surv Ophthalmol 51 2006 364-380.
13. Aiello LP., Avery RL., Arrigg PG., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1994 1480-1487.
14. Miller JW., Adamis AP., Shima DT., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model Am J Pathol 145 1994 574-584.
15. Pierce EA., Avery RL., Foley ED., et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization Proc Natl Acad Sci U S A 92 1995 905-909.
16. Adamis AP., Miller JW., Bernal MT., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am J Ophthalmol 118 1994 445-450.
17. Avery RL Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment Retina 26 2006 352-354.
18. Cai J., Kehoe O., Smith GM., et al. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy Invest Ophthalmol Vis Sci 49 2008 2163-2171.
19. Takagi H., Koyama S., Seike H., et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization Invest Ophthalmol Vis Sci 44 2003 393-402.
20. Geraldes P., Hiraoka-Yamamoto J., Matsumoto M., et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy Nat Med 15 2009 1298-1306.
21. Watanabe D., Suzuma K., Matsui S., et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy N Engl J Med 353 2005 782-792.
22. Tong Z., Yang Z., Patel S., et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications Proc Natl Acad Sci U S A 105 2008 6998-7003.
23. Abhary S., Burdon KP., Casson RJ., et al. Association between erythropoietin gene polymorphisms and diabetic retinopathy Arch Ophthalmol 128 2010 102-106.
24. Ogata N., Tombran-Tink J., Nishikawa M., et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment Am J Ophthalmol 132 2001 378-382.
25. Praidou A., Androudi S., Brazitikos P., et al. Angiogenic growth factors and their inhibitors in diabetic retinopathy Curr Diabetes Rev 6 2010 304-312.
26. Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings Ophthalmology 85 1978 82-106.
27. Shimizu K., Kobayashi Y., Muraoka K Midperipheral fundus involvement in diabetic retinopathy Ophthalmology 88 1981 601-612.
28. Muraoka K., Shimizu K Intraretinal neovascularization in diabetic retinopathy Ophthalmology 91 1984 1440-1446.
29. Kohner EM., Dollery CT., Bulpitt CJ Cotton-wool spots in diabetic retinopathy Diabetes 18 1969 691-704.
30. Kohner EM., Dollery CT The rate of formation and disappearance of microaneurysms in diabetic retinopathy Trans Ophthalmol Soc U K 90 1970 369-374.
31. Davis MD Vitreous contraction in proliferative diabetic retinopathy Arch Ophthalmol 74 1965 741-751.
32. Taylor E., Dobree JH Proliferative diabetic retinopathy. Site and size of initial lesions Br J Ophthalmol 54 1970 11-18.
33. Diabetic Retinopathy Study Report number 6. Design, methods, and baseline results. Report number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy Study Research Group Invest Ophthalmol Vis Sci 21 1981 1-226.
34. Prud’homme G., Rand L The Diabetic Retinopathy Study Research Group: distribution of maximum grade of lesion in proliferative diabetic retinopathy Invest Ophthalm Vis Sci 20 Suppl 1981 59.
35. Joondeph BC., Joondeph HC., Flood TP Foveal neovascularization in diabetic retinopathy Arch Ophthalmol 105 1987 1672-1675.
36. Chew EY., Murphy RP., Newsome DA., et al. Parafoveal telangiectasis and diabetic retinopathy Arch Ophthalmol 104 1986 71-75.
37. Early Treatment Diabetic Retinopathy Study Research Group Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report no. 10 Ophthalmology 98 1991 786-806.
38. Wilson PJ., Ellis JD., MacEwen CJ., et al. Screening for diabetic retinopathy: a comparative trial of photography and scanning laser ophthalmoscopy Ophthalmologica 224 2010 251-257.
39. Oliver SC., Schwartz SD Peripheral vessel leakage (PVL): a new angiographic finding in diabetic retinopathy identified with ultra wide-field fluorescein angiography Semin Ophthalmol 25 2010 27-33.
40. Schwartz JS., Pavan PR Optic disc edema Int Ophthalmol Clin 24 1984 83-91.
41. Kampik A., Kenyon KR., Michels RG., et al. Epiretinal and vitreous membranes. Comparative study of 56 cases Arch Ophthalmol 99 1981 1445-1454.
42. Nork TM., Wallow IH., Sramek SJ., et al. Muller’s cell involvement in proliferative diabetic retinopathy Arch Ophthalmol 105 1987 1424-1429.
43. Dobree JH Proliferative diabetic retinopathy: evolution of the retinal lesions Br J Ophthalmol 48 1964 637-649.
44. Bandello F., Gass JD., Lattanzio R., et al. Spontaneous regression of neovascularization at the disk and elsewhere in diabetic retinopathy Am J Ophthalmol 122 1996 494-501.
45. Tolentino FI., Lee PF., Schepens CL Biomicroscopic study of vitreous cavity in diabetic retinopathy Arch Ophthalmol 75 1966 238-246.
46. Anderson B Jr., Activity and diabetic vitreous hemorrhages Ophthalmology 87 1980 173-175.
47. Tasman W Diabetic vitreous hemorrhage and its relationship to hypoglycemia Mod Probl Ophthalmol 20 1979 413-414.
48. Larsen HW Diabetic retinopathy. An ophthalmoscopic study with a discussion of the morphologic changes and the pathogenetic factors in this disease Acta Ophthalmol Suppl 60 1960 1-89.
49. Bresnick GH., Haight B., De Venecia G Retinal wrinkling and macular heterotopia in diabetic retinopathy Arch Ophthalmol 97 1979 1890-1895.
50. Ramsay WJ., Ramsay RC., Purple RL., et al. Involutional diabetic retinopathy Am J Ophthalmol 84 1977 851-858.
51. Beetham WP Visual prognosis of proliferating diabetic retinopathy Br J Ophthalmol 47 1963 611-619.
52. Klein R., Klein BE., Moss SE., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years Arch Ophthalmol 102 1984 520-526.
53. Klein R., Klein BE., Moss SE., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years Arch Ophthalmol 102 1984 527-532.
54. Klein R., Klein BE., Moss SE., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema Ophthalmology 102 1995 7-16.
55. Diabetic Retinopathy Vitrectomy Study Research Group Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2 Arch Ophthalmol 103 1985 1644-1652.
56. Diabetic Retinopathy Vitrectomy Study Research Group Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial - Diabetic Retinopathy Vitrectomy Study report 4 Ophthalmology 95 1988 1321-1334.
57. Diabetic Retinopathy Vitrectomy Study Research Group Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 3 Ophthalmology 95 1988 1307-1320.
58. Diabetic Retinopathy Vitrectomy Study Research Group Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 5 Arch Ophthalmol 108 1990 958-964.
59. Aiello LM., Rand LI., Briones JC., et al. Diabetic retinopathy in Joslin Clinic patients with adult-onset diabetes Ophthalmology 88 1981 619-623.
60. Zhang X., Saaddine JB., Chou CF., et al. Prevalence of diabetic retinopathy in the United States, 2005-2008 JAMA 304 2010 649-656.
61. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 329 1993 977-986.
62. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837-853.
63. Diabetes Control and Complications Trial Research Group Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial Ophthalmology 102 1995 647-661.
64. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Arch Ophthalmol 113 1995 36-51.
65. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus JAMA 287 2002 2563-2569.
66. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study JAMA 290 2003 2159-2167.
67. Gerstein HC., Miller ME., Byington RP., et al. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545-2559.
68. Holman RR., Paul SK., Bethel MA., et al. 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577-1589.
69. White NH., Sun W., Cleary PA., et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial Arch Ophthalmol 126 2008 1707-1715.
70. White NH., Cleary PA., Dahms W., et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT) J Pediatr 139 2001 804-812.
71. Davis MD., Fisher MR., Gangnon RE., et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study (ETDRS) report no. 18 Invest Ophthalmol Vis Sci 39 1998 233-252.
72. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial Arch Ophthalmol 116 1998 874-886.
73. Dahl-Jorgensen K., Brinchmann-Hansen O., Hanssen KF., et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study Br Med J (Clin Res Ed) 290 1985 811-815.
74. Dandona P., Bolger JP., Boag F., et al. Rapid development and progression of proliferative retinopathy after strict diabetic control Br Med J (Clin Res Ed) 290 1985 895-896.
75. Funatsu H., Yamashita H., Ohashi Y., et al. Effect of rapid glycemic control on progression of diabetic retinopathy Jpn J Ophthalmol 36 1992 356-367.
76. Lauritzen T., Frost-Larsen K., Larsen HW., et al. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy Diabetes 34 Suppl 3 1985 74-79.
77. Brinchmann-Hansen O., Dahl-Jorgensen K., Hanssen KF., et al. The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy Arch Ophthalmol 106 1988 1242-1246.
78. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. The Kroc Collaborative Study Group N Engl J Med 311 1984 365-372.
79. Agardh CD., Eckert B., Agardh E Irreversible progression of severe retinopathy in young type I insulin-dependent diabetes mellitus patients after improved metabolic control J Diabetes Complications 6 1992 96-100.
80. Ernest JT., Goldstick TK., Engerman RL Hyperglycemia impairs retinal oxygen autoregulation in normal and diabetic dogs Invest Ophthalmol Vis Sci 24 1983 985-989.
81. Grunwald JE., Brucker AJ., Braunstein SN., et al. Strict metabolic control and retinal blood flow in diabetes mellitus Br J Ophthalmol 78 1994 598-604.
82. Grunwald JE., Brucker AJ., Schwartz SS., et al. Diabetic glycemic control and retinal blood flow Diabetes 39 1990 602-607.
83. Bain SC., Gill GV., Dyer PH., et al. Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort) Diabet Med 20 2003 808-811.
84. Keenan HA., Costacou T., Sun JK., et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year Medalist study Diabetes Care 30 2007 1995-1997.
85. Sun JK., Keenan HA., Cavallerano JD., et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study Diabetes Care. 34 4 2011 968-974.
86. Ismail-Beigi F., Craven T., Banerji MA., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 2010 419-430.
87. Patel A., MacMahon S., Chalmers J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829-840.
88. Chew EY., Ambrosius WT., Davis MD., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 2010 233-244.
89. Keech AC., Mitchell P., Summanen PA., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687-1697.
90. Chaturvedi N., Sjolie AK., Stephenson JM., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus Lancet 351 1998 28-31.
91. Chaturvedi N., Porta M., Klein R., et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet 372 2008 1394-1402.
92. Sjolie AK., Klein R., Porta M., et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial Lancet 372 2008 1385-1393.
93. Mauer M., Zinman B., Gardiner R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 2009 40-51.
94. Pershadsingh HA., Moore DM PPARgamma agonists: potential as therapeutics for neovascular retinopathies PPAR Res 2008 2008 164273.
95. Shen LQ., Child A., Weber GM., et al. Rosiglitazone and delayed onset of proliferative diabetic retinopathy Arch Ophthalmol 126 2008 793-799.
96. Panigrahy D., Singer S., Shen LQ., et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis J Clin Invest 110 2002 923-932.
97. Chew EY., Klein ML., Ferris FL III., et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) report no. 22 Arch Ophthalmol 114 1996 1079-1084.
98. Biasotti A., Houssay BA Phlorrhizin diabetes in fasting or fed hypophysectomized dogs J Physiol 77 1932 81-91.
99. Luft R., Olivecrona H., Sjogren B [Hypophysectomy in man.] Nord Med 47 1952 351-354.
100. Poulsen JE Recovery from retinopathy in a case of diabetes with Simmonds’ disease Diabetes 2 1953 7-12.
101. Poulsen JE Diabetes and anterior pituitary insufficiency. Final course and postmortem study of a diabetic patient with Sheehan’s syndrome Diabetes 15 1966 73-77.
102. Kohner EM., Joplin GF., Blach RK., et al. Pituitary ablation in the treatment of diabetic retinopathy. (A randomized trial) Trans Ophthalmol Soc U K 92 1972 79-90.
103. Panisset A., Kohner EM., Cheng H., et al. Diabetic retinopathy: new vessels arising from the optic disc. II. Response to pituitary ablation by yttrium 90 implant Diabetes 20 1971 824-833.
104. Kohner EM., Hamilton AM., Joplin GF., et al. Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation Diabetes 25 1976 104-110.
105. Smith LE., Shen W., Perruzzi C., et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor Nat Med 5 1999 1390-1395.
106. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group (2001) The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy Ophthalmology 108 2001 2266-2272.
107. Boehm BO., Lang GK., Jehle PM., et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy Horm Metab Res 33 2001 300-306.
108. Beetham WP Visual prognosis of proliferating diabetic retinopathy Br J Ophthalmol 47 1963 611-619.
109. Aiello LM, Beetham WP, Balodimos MC, et al. Ruby laser photocoagulation in treatment of diabetic proliferating retinopathy: Preliminary report. In: Goldberg MF, Fine SL, editors. Symposium on the treatment of diabetic retinopathy. Arlington, VA: U S Department of Health, Education, and Welfare, 1968. pp. 437-63.
110. Meyer-Schwickerath G [Light coagulation; a method for treatment and prevention of the retinal detachment.] Albrecht Von Graefes Arch Ophthalmol 156 1954 2-34.
111. Okun E., Cibis PA The role of photocoagulation in the therapy of proliferative diabetic retinopathy Arch Ophthalmol 75 1966 337-352.
112. Wetzig PC., Jepson CN Treatment of diabetic retinopathy by light coagulation Am J Ophthalmol 62 1966 459-465.
113. Wetzig PC., Worlton JT Treatment of diabetic retinopathy by light-coagulation: a preliminary study Br J Ophthalmol 47 1963 539-541.
114. Beetham WP., Aiello LM., Balodimos MC., et al. Ruby-laser photocoagulation of early diabetic neovascular retinopathy: preliminary report of a long-term controlled study Trans Am Ophthalmol Soc 67 1969 39-67.
115. Beetham WP., Aiello LM., Balodimos MC., et al. Ruby laser photocoagulation of early diabetic neovascular retinopathy. Preliminary report of a long-term controlled study Arch Ophthalmol 83 1970 261-272.
116. Meyer-Schwickerath RE., Schott K Diabetic retinopathy and photocoagulation Am J Ophthalmol 66 1968 597-603.
117. Okun E The effectiveness of photocoagulation in the therapy of proliferative diabetic retinopathy (PDR). (A controlled study in 50 patients Trans Am Acad Ophthalmol Otolaryngol 72 1968 246-252.
118. Glaser BM., Campochiaro PA., Davis JL Jr., et al. Retinal pigment epithelial cells release an inhibitor of neovascularization Arch Ophthalmol 103 1985 1870-1875.
119. Ederer F., Hiller R Clinical trials, diabetic retinopathy and photocoagulation. A reanalysis of five studies Surv Ophthalmol 19 1975 267-286.
120. Stefansson E., Hatchell DL., Fisher BL., et al. Panretinal photocoagulation and retinal oxygenation in normal and diabetic cats Am J Ophthalmol 101 1986 657-664.
121. Gerstein DD., Dantzker DR Retinal vascular changes in hereditary visual cell degeneration Arch Ophthalmol 81 1969 99-105.
122. Molnar I., Poitry S., Tsacopoulos M., et al. Effect of laser photocoagulation on oxygenation of the retina in miniature pigs Invest Ophthalmol Vis Sci 26 1985 1410-1414.
123. Weiter JJ., Zuckerman R The influence of the photoreceptor-RPE complex on the inner retina. An explanation for the beneficial effects of photocoagulation Ophthalmology 87 1980 1133-1139.
124. Wolbarsht ML., Landers MB III., The rationale of photocoagulation therapy for proliferative diabetic retinopathy: a review and a model Ophthalmic Surg 11 1980 235-245.
125. Grunwald JE., Riva CE., Brucker AJ., et al. Altered retinal vascular response to 100% oxygen breathing in diabetes mellitus Ophthalmology 91 1984 1447-1452.
126. Patel V., Rassam S., Newsom R., et al. Retinal blood flow in diabetic retinopathy BMJ 305 1992 678-683.
127. Stefansson E., Machemer R., de Juan E Jr., et al. Retinal oxygenation and laser treatment in patients with diabetic retinopathy Am J Ophthalmol 113 1992 36-38.
128. Cheng H Multicentre trial of xenon-arc photocoagulation in the treatment of diabetic retinopathy. A Randomized controlled study. Interim report Trans Ophthalmol Soc U K 95 1975 351-357.
129. Editorial: The diabetic retinopathy study Arch Ophthalmol 90 1973 347-348.
130. Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings. Diabetic Retinopathy Study report 8 Ophthalmology 88 1981 583-600.
131. Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report 5 Dev Ophthalmol 2 1981 248-261.
132. Rand LI., Prud’homme GJ., Ederer F., et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) report 10 Invest Ophthalmol Vis Sci 26 1985 983-991.
133. Little HL., Rosenthal AR., Dellaporta A., et al. The effect of pan-retinal photo-coagulation on rubeosis iridis Am J Ophthalmol 81 1976 804-809.
134. Okun E., Johnston GP., Boniuk I., et al. Xenon arc photocoagulation of proliferative diabetic retinopathy. A review of 2688 consecutive eyes in the format of the Diabetic Retinopathy Study Ophthalmology 91 1984 1458-1463.
135. British Multicentre Study Group Photocoagulation for proliferative diabetic retinopathy: a randomised controlled clinical trial using the xenon-arc Diabetologia 26 1984 109-115.
136. Hercules BL., Gayed II., Lucas SB., et al. Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser Br J Ophthalmol 61 1977 555-563.
137. Early Treatment Diabetic Retinopathy Study Research Group Early photocoagulation for diabetic retinopathy. ETDRS report no. 9 Ophthalmology 98 1991 766-785.
138. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. ETDRS report no. 1 Arch Ophthalmol 103 1985 1796-1806.
139. Early Treatment Diabetic Retinopathy Study Research Group Effects of aspirin treatment on diabetic retinopathy. ETDRS report no. 8 Ophthalmology 98 1991 757-765.
140. Early Treatment Diabetic Retinopathy Study Research Group Techniques for scatter and local photocoagulation treatment of diabetic retinopathy. ETDRS report no. 3 Int Ophthalmol Clin 27 1987 254-264.
141. Ferris F Early photocoagulation in patients with either type I or type II diabetes Trans Am Ophthalmol Soc 94 1996 505-537.
142. Chey EY for the Krypton Argon Regression Neovascularization Study Research Group Randomized comparison of krypton versus argon scatter photocoagulation for diabetic disc neovascularization: KARNS Study report number 1 Ophthalmology 100 1993 1655-1664.
143. Meyer-Schwickerath G., Gerke E Bjerrum lecture. Treatment of diabetic retinopathy with photocoagulation. Results of photocoagulation therapy of proliferative retinopathy in childhood-onset and maturity-onset diabetes and an approach to the dosage in photocoagulation Acta Ophthalmol (Copenh) 61 1983 756-768.
144. Chew EY., Mills JL., Metzger BE., et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study Diabetes Care 18 1995 631-637.
145. Klein BE., Moss SE., Klein R Effect of pregnancy on progression of diabetic retinopathy Diabetes Care 13 1990 34-40.
146. Mathiesen ER., Ronn B., Storm B., et al. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study Diabet Med 12 1995 482-487.
147. McDonald HR., Schatz H Macular edema following panretinal photocoagulation Retina 5 1985 5-10.
148. McDonald HR., Schatz H Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy Ophthalmology 92 1985 388-393.
149. Meyers SM Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy Am J Ophthalmol 90 1980 210-216.
150. Ferris FL III., Podgor MJ., Davis MD Macular edema in diabetic retinopathy study patients. Diabetic Retinopathy Study report number 12 Ophthalmology 94 1987 754-760.
151. Early Treatment Diabetic Retinopathy Study Research Group Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report no. 2 Ophthalmology 94 1987 761-774.
152. Elman MJ., Aiello LP., Beck RW., et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064-1077.
153. Sultan MB., Zhou D., Loftus J., et al. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema Ophthalmology 118 2011 1107-1118.
154. Arevalo JF., Sanchez JG., Fromow-Guerra J., et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up Graefes Arch Clin Exp Ophthalmol 247 2009 735-743.
155. Googe J., Brucker AJ., Bressler NM., et al. for the Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation Retina 31 6 2011 1009-1027.
156. Shimura M., Yasuda K., Nakazawa T., et al. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision Ophthalmology 110 2003 2386-2394.
157. Diabetic Retinopathy Clinical Research Network Brucker AJ., Qin H., Antoszyk AN., et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings Arch Ophthalmol 127 2009 132-140.
158. Pavan PR., Folk JC., Weingeist TA., et al. Diabetic rubeosis and panretinal photocoagulation Arch Ophthalmol 101 1983 882-884.
159. Blumenkranz MS., Yellachich D., Andersen DE., et al. Semiautomated patterned scanning laser for retinal photocoagulation Retina 26 2006 370-376.
160. Jain A., Blumenkranz MS., Paulus Y., et al. Effect of pulse duration on size and character of the lesion in retinal photocoagulation Arch Ophthalmol 126 2008 78-85.
161. Muqit MM, Sanghvi C, McLauchlan R, et al. Study of clinical applications and safety for Pascal((R)) laser photocoagulation in retinal vascular disorders. Acta Ophthalmol 2010. Epub ahead of print February 16, 2010; PMID 20163363.
162. Velez-Montoya R., Guerrero-Naranjo JL., Gonzalez-Mijares CC., et al. Pattern scan laser photocoagulation: safety and complications, experience after 1301 consecutive cases Br J Ophthalmol 94 2010 720-724.
163. Kriechbaum K., Bolz M., Deak GG., et al. High-resolution imaging of the human retina in vivo after scatter photocoagulation treatment using a semiautomated laser system Ophthalmology 117 2010 545-551.
164. Liang JC., Huamonte FU Reduction of immediate complications after panretinal photocoagulation Retina 4 1984 166-170.
165. Doft BH., Blankenship GW Single versus multiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy Ophthalmology 89 1982 772-779.
166. Bandello F., Brancato R., Lattanzio R., et al. Double-frequency Nd:YAG laser vs argon-green laser in the treatment of proliferative diabetic retinopathy: randomized study with long-term follow-up Lasers Surg Med 19 1996 173-176.
167. Bandello F., Brancato R., Trabucchi G., et al. Diode versus argon-green laser panretinal photocoagulation in proliferative diabetic retinopathy: a randomized study in 44 eyes with a long follow-up time Graefes Arch Clin Exp Ophthalmol 231 1993 491-494.
168. Doft BH., Blankenship G Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy Ophthalmology 91 1984 1453-1457.
169. Blankenship GW A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy Ophthalmology 95 1988 170-177.
170. Vander JF., Duker JS., Benson WE., et al. Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation Ophthalmology 98 1991 1575-1579.
171. Rogell GD Incremental panretinal photocoagulation. Results in treating proliferative diabetic retinopathy Retina 3 1983 308-311.
172. Reddy VM., Zamora RL., Olk RJ Quantitation of retinal ablation in proliferative diabetic retinopathy Am J Ophthalmol 119 1995 760-766.
173. Vine AK The efficacy of additional argon laser photocoagulation for persistent, severe proliferative diabetic retinopathy Ophthalmology 92 1985 1532-1537.
174. Early Treatment Diabetic Retinopathy Study Research Group Case reports to accompany Early Treatment Diabetic Retinopathy Study reports 3 and 4 Int Ophthalmol Clin 27 1987 273-333.
175. Dogru M., Kaderli B., Gelisken O., et al. Ocular surface changes with applanation contact lens and coupling fluid use after argon laser photocoagulation in noninsulin-dependent diabetes mellitus Am J Ophthalmol 138 2004 381-388.
176. Bloom SM., Mahl CF., Schiller SB Lenticular burns following argon panretinal photocoagulation Br J Ophthalmol 76 1992 630-631.
177. Moriarty AP., Spalton DJ., Shilling JS., et al. Breakdown of the blood-aqueous barrier after argon laser panretinal photocoagulation for proliferative diabetic retinopathy Ophthalmology 103 1996 833-838.
178. Patel JI., Jenkins L., Benjamin L., et al. Dilated pupils and loss of accommodation following diode panretinal photocoagulation with sub-tenon local anaesthetic in four cases Eye (Lond) 16 2002 628-632.
179. Fong DS., Girach A., Boney A Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review Retina 27 2007 816-824.
180. Mendrinos E., Donati G., Pournaras CJ Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib Acta Ophthalmol 87 2009 683-684.
181. Avery RL., Pearlman J., Pieramici DJ., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 2006 1695.e1-1695.e15.
182. Jorge R., Costa RA., Calucci D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) Retina 26 2006 1006-1013.
183. Erdol H., Turk A., Akyol N., et al. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy Retina 30 2010 570-577.
184. Mirshahi A., Roohipoor R., Lashay A., et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial Eur J Ophthalmol 18 2008 263-269.
185. Tonello M., Costa RA., Almeida FP., et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study) Acta Ophthalmol 86 2008 385-389.
186. Takahashi M., Trempe CL., Maguire K., et al. Vitreoretinal relationship in diabetic retinopathy. A biomicroscopic evaluation Arch Ophthalmol 99 1981 241-245.
187. Ono R., Kakehashi A., Yamagami H., et al. Prospective assessment of proliferative diabetic retinopathy with observations of posterior vitreous detachment Int Ophthalmol 26 2005 15-19.
188. Rheaume MA., Vavvas D Pharmacologic vitreolysis Semin Ophthalmol 25 2010 295-302.
189. Gandorfer A Objective of pharmacologic vitreolysis Dev Ophthalmol 44 2009 1-6.
190. Kuppermann BD., Thomas EL., de Smet MD., et al. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage Vitrase for Vitreous Hemorrhage Study Groups Am J Ophthalmol 140 2005 573-584.
191. Stalmans P., Delaey C., de Smet MD., et al. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial) Retina 30 2010 1122-1127.
192. Goldenberg DT., Trese MT Pharmacologic vitreodynamics and molecular flux Dev Ophthalmol 44 2009 31-36.
193. Machemer R., Buettner H., Norton EW., et al. Vitrectomy: a pars plana approach Trans Am Acad Ophthalmol Otolaryngol 75 1971 813-820.